Cargando…
KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission
Renewed global efforts toward malaria eradication have highlighted the need for novel antimalarial agents with activity against multiple stages of the parasite life cycle. We have previously reported the discovery of a novel class of antimalarial compounds in the imidazolopiperazine series that have...
Ejemplares similares
-
Imidazolopiperazines:
Lead Optimization of the Second-Generation Antimalarial Agents
por: Nagle, Advait, et al.
Publicado: (2012) -
AAALAC International Standards and Accreditation Process
por: Gettayacamin, Montip, et al.
Publicado: (2017) -
Imidazolopiperazines: Hit to Lead Optimization of New Antimalarial Agents
por: Wu, Tao, et al.
Publicado: (2011) -
Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia
por: Marfurt, Jutta, et al.
Publicado: (2021) -
Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry
por: Wirjanata, Grennady, et al.
Publicado: (2015)